Management of Acute Massive Pulmonary Embolism with Hypotension and Right Ventricular Dysfunction

Diagnosis and Risk Stratification

The American College of Chest Physicians recommends that patients with massive PE be identified based on initial hypotension (systolic BP <90 mmHg) and right ventricular dysfunction, as seen in this patient with an initial systolic BP of 88 mmHg 1, 3
Right ventricular dysfunction and dilatation on echocardiography are key criteria for diagnosing massive PE, with elevated RVSP (52 mmHg) indicating significant RV afterload stress 4, 5, 6

The European Society of Cardiology recommends administering alteplase 100 mg as a continuous intravenous infusion over 2 hours via peripheral vein for patients with massive PE, as this is the FDA-approved accelerated regimen 1, 2
Peripheral venous administration is preferred over pulmonary artery catheter, and short infusion times (2 hours) are superior to prolonged infusions (24 hours) 1
In patients with cardiac arrest or rapidly deteriorating condition, 50 mg alteplase IV bolus may be administered immediately, as recommended by the British Thoracic Society 3, 2

The American Heart Association states that in life-threatening massive PE, most contraindications to thrombolysis should be ignored given the high mortality without treatment, but absolute contraindications include prior intracranial hemorrhage, known structural intracranial vascular disease, and known malignant intracranial neoplasm 3, 6

The American College of Chest Physicians recommends withholding heparin anticoagulation during the 2-hour alteplase infusion, and resuming unfractionated heparin 3 hours after completion of alteplase infusion, using weight-adjusted dosing 2, 3

Thrombolysis significantly reduces the risk of persistent RV dysfunction and chronic thromboembolic pulmonary hypertension, with improved 6-minute walk distance and NYHA functional class at follow-up, as reported by the European Society of Cardiology 6
No patients treated with alteplase demonstrated increased RVSP at 6-month follow-up, compared to 27% of heparin-only patients, highlighting the importance of thrombolytic therapy in reducing long-term complications 6

The British Thoracic Society recommends continuous cardiac monitoring, serial blood pressure measurements, and oxygen saturation monitoring during treatment, as well as periodic laboratory monitoring to assess for bleeding complications 1, 3
Major bleeding occurs in approximately 8-9% of patients receiving thrombolysis for PE, with intracranial hemorrhage in approximately 1%, emphasizing the need for careful monitoring and management of bleeding risk 6

If thrombolysis is absolutely contraindicated, fails, or shock is likely to cause death before thrombolysis can take effect, surgical pulmonary embolectomy or catheter-assisted thrombus removal may be considered, as recommended by the American College of Chest Physicians 1, 3